leisure time -WSS

leisure time

author：comprehensive 2025-08-17 00:02:29 - browse：254

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Eli Lilly to pay $200M for Beam’s stake in gene

WSS

Chimpanzees, like humans and whales, get menopause: Study

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Roche drug slashes death risk in early

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

STAT Summit: How researchers deal with rejection

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why a market frenzy over new weight loss drugs defies logic

Medical records are filled with copy

Testing for cancer recurrence creates a new limbo for patients

As demand for Covid shots wanes, Moderna seeks its next success

Questions loom on AstraZeneca cancer drug as safety concerns ebb

What does generative AI mean for health care? We asked experts

STAT Summit: How researchers deal with rejection

focus

Emergency medicine has repudiated 'excited delirium.' Now what?

Readout LOUD podcast: Live from the 2023 STAT Summit

The pink breast cancer awareness ribbon needs a redesign

The pink breast cancer awareness ribbon needs a redesign

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Wikipedia

leisure time

hotspot

leisure time